News | July 19, 2007

Dune Medical Devices Honored for Novel Cancer Probe

July 20, 2007 - Dune Medical Devices (Caesarea, Israel) received the 2007 Frost & Sullivan European Technology Innovation of the Year Award in surgical oncology for its novel intraoperative breast cancer probe. Using Radio Frequency (RF) Spectroscopy, the device provides surgeons with the malignancy status of breast cancer margins in real-time.

The Dune hand-held probe reportedly holds significant promise to reduce re-excision procedures, improve patient outcomes and minimize surgical expenses.

“Dune's real-time tissue probe and portable console have the potential to satisfy a major unmet surgical oncology need,” noted Frost & Sullivan Research Director Girish Solanki. “The device provides doctors with simple, real-time determination of margin malignancy status at the desired locus while the patient is still in the operating room. It helps improve surgical accuracy, allowing doctors to meet procedure goals more easily without the need for a second surgery.”

"Today, breast conservation surgery aims to excise tumors completely, along with a rim of surrounding healthy tissue. However, determining the status of this tissue is difficult, and a large number of women must undergo a re-excision to achieve desired surgical results. This is because an accurate and reliable method for accessing margin status intraoperatively has not existed until now. The Dune probe fills an important need," added Solanki.

In a recent study the Dune probe detected 86 percent of positive tumor margins that were otherwise missed by current standard of care, potentially allowing surgeons to reshave the tumor cavity and eliminate an additional surgery. In a second study, the device identified 20 out of 21 DCIS sites as verified by post-operative pathology reports.

"Among the probe's multiple advantages are intraoperative detection of positive resection margins in breast conservation surgery and the quantification of dozens of measurement points within minutes, along with simple operation supporting current breast surgical workflow,” said Solanki.

For more information: www.dunemedical.com

Related Content

Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Hologic rings Nasdaq bell for breast cancer awareness
News | Breast Imaging | October 02, 2017
Hologic Inc. announced that Steve MacMillan, the company's chairman, president and CEO, joined selected employees to...
Hologic Announces Availability of Brevera Breast Biopsy System With CorLumina Imaging Technology
Technology | Breast Biopsy Systems | August 31, 2017
Hologic Inc. announced U.S. commercial availability of the Brevera breast biopsy system with CorLumina imaging...
Top list of stories, article, videos for breast imaging.
Feature | Breast Imaging | August 30, 2017 | Dave Fornell
August 30, 2017 — This is a list of the top breast imaging content so far for 2017.
Hologic, ECR 2017, breast cancer screening solutions, Affirm prone biopsy system

The Affirm prone biopsy system. Image courtesy of Hologic.

News | Breast Imaging | March 14, 2017
Hologic Inc. highlighted its portfolio of innovative breast cancer screening and interventional products, including new...
Sponsored Content | Videos | Women's Health | November 16, 2016
The purpose of this exploratory video roundtable is to examine the state of breast biopsies today and to communicate...
stereotactic breast imaging

This image shows a 52-year-old patient with benign calcifications in her pre-stereotactic breast biopsy screening.

Feature | Breast Biopsy Systems | November 01, 2016 | By Laura Shepardson, M.D.
Recently, I was invited to participate in a...
Hologic, FDA approval, launch, Affirm prone biopsy system, breast cancer, women's health
Technology | Breast Biopsy Systems | April 21, 2016
Hologic Inc. announced the U.S. Food and Drug Administration (FDA) clearance and commercial launch of the Affirm prone...

Breast surgeon Michael Cross, M.D., has done clinical research on the DotMed BioZorb surgical marker. (Photo courtesy of DotMed)

Feature | Women's Health | November 11, 2015
Breast cancer research conducted by two Fayetteville, Ark., medical groups highlights their success in pioneering use
Hologic, RSNA 2015, breast tomosynthesis, breast biopsy systems

I-View contrast enhanced 2-D mammography image courtesy of Hologic

Technology | Breast Imaging | October 02, 2015
October 2, 2015 — At the Radiological Society of North America’s (RSNA) 2015 annual meeting, Hologic will emphasize i
Overlay Init